This compound is primarily utilized in biomedical research, particularly in the field of targeted protein degradation. It functions as a proteolysis-targeting chimera (PROTAC) designed to specifically degrade BRD4, a protein implicated in various cancers and inflammatory diseases. By facilitating the ubiquitination and subsequent degradation of BRD4, it helps in studying the role of this protein in disease pathways and evaluating its potential as a therapeutic target. Its application is significant in developing novel cancer therapies, as inhibiting BRD4 can disrupt the growth and survival of cancer cells. Additionally, it serves as a valuable tool in understanding epigenetic regulation and gene expression mechanisms.